Alternatively, since DDAs disrupt the CDCP1/EGFR/Src ternary complex, in addition to effectively inhibiting the growth of HER2-positive malignancies [13], DDAs may be useful for the treatment of breast tumors that overexpress EGFR, or for blocking metastasis driven by signaling via the CDCP1/EGFR/Src ternary complex. This evidence concerns the gene EGFR and breast neoplasm.